Adagene Inc (ADAG) - News Archive

In a strategic move that signals the ongoing evolution of cancer therapeutics, Adagene Inc. has announced a licensing agreement with Third Arc Bio, Inc. to develop two masked CD3 T cell engagers utilizing Adagene’s prop...

New Insights into Adagene s ADG126 and Implications for Financial HealthAt the recently concluded Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, Adagene Inc. presented groundbreaking data that highlight...

Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-Stable Colorectal Cancer: Insights from ESMO Congress R...

Adagene, a leading biotechnology company, recently announced the progress and expansion of its clinical collaboration program for their promising drug, ADG126 (also known as muzastotug), in combination with KEYTRUDA (pe...

The treatment landscape for metastatic microsatellite-stable (MSS) colorectal cancer (CRC) has been evolving rapidly, with immunotherapy playing a significant role. In a recent study, Adagene presented interim results h...